| 1 |
Wu Y, Sun T, Chen M, Munir M, Liu H. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front Cell Infect Microbiol 2023;13. [DOI: 10.3389/fcimb.2023.1142172] [Reference Citation Analysis]
|
| 2 |
Ahn R, Cui Y, White FM. Antigen discovery for the development of cancer immunotherapy. Semin Immunol 2023;66:101733. [PMID: 36841147 DOI: 10.1016/j.smim.2023.101733] [Reference Citation Analysis]
|
| 3 |
Floerchinger A, Klein JE, Finkbeiner MSC, Schäfer TE, Fuchs G, Doerner J, Zirngibl H, Ackermann M, Kvasnicka HM, Chester KA, Jäger D, Ball CR, Ungerechts G, Engeland CE. A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors. Cell Death Dis 2023;14:104. [PMID: 36765035 DOI: 10.1038/s41419-023-05624-3] [Reference Citation Analysis]
|
| 4 |
Jiang Y, Zhang H, Wang J, Chen J, Guo Z, Liu Y, Hua H. Exploiting RIG-I-like receptor pathway for cancer immunotherapy. J Hematol Oncol 2023;16:8. [PMID: 36755342 DOI: 10.1186/s13045-023-01405-9] [Reference Citation Analysis]
|
| 5 |
Groeneveldt C, van den Ende J, van Montfoort N. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy? Cytokine Growth Factor Rev 2023:S1359-6101(23)00002-3. [PMID: 36732155 DOI: 10.1016/j.cytogfr.2023.01.002] [Reference Citation Analysis]
|
| 6 |
Cheke RS, Bagwe P, Bhange S, Kharkar PS. Biologicals and small molecules as target-specific cancer chemotherapeutic agents. Medicinal Chemistry of Chemotherapeutic Agents 2023. [DOI: 10.1016/b978-0-323-90575-6.00018-1] [Reference Citation Analysis]
|
| 7 |
Li S, Li Q, Ren Y, Yi J, Guo J, Kong X. HSV: The scout and assault for digestive system tumors. Front Mol Biosci 2023;10:1142498. [PMID: 36926680 DOI: 10.3389/fmolb.2023.1142498] [Reference Citation Analysis]
|
| 8 |
Omole RK, Oluwatola O, Akere MT, Eniafe J, Agboluaje EO, Daramola OB, Ayantunji YJ, Omotade TI, Torimiro N, Ayilara MS, Adeyemi OI, Salinsile OS. Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. Front Pharmacol 2022;13:1082797. [PMID: 36569326 DOI: 10.3389/fphar.2022.1082797] [Reference Citation Analysis]
|
| 9 |
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, Mccomb S, Auer R, Diallo J, Ilkow CS, Bell JC. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1029269] [Reference Citation Analysis]
|
| 10 |
Su Y, Su C, Qin L. Current landscape and perspective of oncolytic viruses and their combination therapies. Transl Oncol 2022;25:101530. [PMID: 36095879 DOI: 10.1016/j.tranon.2022.101530] [Reference Citation Analysis]
|
| 11 |
Wang Z, Zhong H, Liang X, Ni S. Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape. Front Immunol 2022;13:1024921. [DOI: 10.3389/fimmu.2022.1024921] [Reference Citation Analysis]
|
| 12 |
Jafari M, Kadkhodazadeh M, Shapourabadi MB, Goradel NH, Shokrgozar MA, Arashkia A, Abdoli S, Sharifzadeh Z. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Front Immunol 2022;13:1012806. [DOI: 10.3389/fimmu.2022.1012806] [Reference Citation Analysis]
|
| 13 |
Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer 2022;21:196. [PMID: 36221123 DOI: 10.1186/s12943-022-01664-z] [Reference Citation Analysis]
|
| 14 |
Baldari S, Di Modugno F, Nisticò P, Toietta G. Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy. Cancers 2022;14:4706. [DOI: 10.3390/cancers14194706] [Reference Citation Analysis]
|
| 15 |
Corbett V, Hallenbeck P, Rychahou P, Chauhan A. Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. Front Mol Biosci 2022;9:930207. [DOI: 10.3389/fmolb.2022.930207] [Reference Citation Analysis]
|
| 16 |
Ang L, Li J, Dong H, Wang C, Huang J, Li M, Zhao M, Su C, Wu Q. Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer. Bioengineering (Basel) 2022;9:342. [PMID: 35892755 DOI: 10.3390/bioengineering9080342] [Reference Citation Analysis]
|
| 17 |
Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N, Rehman MU. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/3142306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 18 |
Wu C, Qin C, Long W, Wang X, Xiao K, Liu Q. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data 2022;9:92. [PMID: 35855914 DOI: 10.1186/s40537-022-00643-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Cripe TP, Hutzen B, Currier MA, Chen C, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang P. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci Adv 2022;8:eabm1890. [DOI: 10.1126/sciadv.abm1890] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol 2022. [PMID: 35818970 DOI: 10.2217/fon-2022-0440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Wang Q, Ma X, Wu H, Zhao C, Chen J, Li R, Yan S, Li Y, Zhang Q, Song K, Yuan C, Kong B. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer. OncoImmunology 2022;11:2096362. [DOI: 10.1080/2162402x.2022.2096362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Su Y, Li J, Ji W, Wang G, Fang L, Zhang Q, Ang L, Zhao M, Sen Y, Chen L, Zheng J, Su C, Qin L. Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors. J Immunother Cancer 2022;10:e004691. [PMID: 35609942 DOI: 10.1136/jitc-2022-004691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Wang J, Chen C, Wang L, Xie M, Ge X, Wu S, He Y, Mou X, Ye C, Sun Y. Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. Front Oncol 2022;12:872531. [PMID: 35449581 DOI: 10.3389/fonc.2022.872531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 2022;41:142. [PMID: 35428347 DOI: 10.1186/s13046-022-02349-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 25 |
Yang L, Ning Q, Tang S, Cui D. Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/8052212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Lei W, Ye Q, Hao Y, Chen J, Huang Y, Yang L, Wang S, Qian W. CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma. Blood Cancer J 2022;12:35. [PMID: 35228544 DOI: 10.1038/s41408-022-00634-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Hao S, Inamdar V, Sigmund E, Zhang F, Stephan S, Watson C, Weaver S, Nielsen U, Stephan M. BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology. Journal of Controlled Release 2022;342:14-25. [DOI: 10.1016/j.jconrel.2021.12.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Mahasa KJ, Ouifki R, Eladdadi A, Pillis LD; Department of Mathematics and Computer Science, National University of Lesotho, Roma 180, Maseru, Lesotho, Department of Mathematics and Applied Mathematics, North-West University, Mafikeng campus, Private Bag X2046, Mmabatho 2735, South Africa, The College of Saint Rose, Albany, NY, USA, Harvey Mudd College, Claremont, CA, USA. . MBE 2022;19:4429-57. [DOI: 10.3934/mbe.2022205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Floerchinger A, Engeland CE. NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2441-8_12] [Reference Citation Analysis]
|
| 30 |
Kontermann RE, Ungerechts G, Nettelbeck DM. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs 2021;13:1982447. [PMID: 34747345 DOI: 10.1080/19420862.2021.1982447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Leung EYL, McNeish IA. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. Viruses 2021;13:1450. [PMID: 34452316 DOI: 10.3390/v13081450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 32 |
Nettelbeck DM, Leber MF, Altomonte J, Angelova A, Beil J, Berchtold S, Delic M, Eberle J, Ehrhardt A, Engeland CE, Fechner H, Geletneky K, Goepfert K, Holm PS, Kochanek S, Kreppel F, Krutzke L, Kühnel F, Lang KS, Marchini A, Moehler M, Mühlebach MD, Naumann U, Nawroth R, Nüesch J, Rommelaere J, Lauer UM, Ungerechts G. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses 2021;13:1420. [PMID: 34452286 DOI: 10.3390/v13081420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
